Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: A pilot study

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 32, Issue 1, 2015, Pages 43-52

  Strookappe, B ^a,b   Elfferich, M ^b   Swigris, J ^c   Verschoof, A ^b   Verschakelen, J ^b,d   Knevel, T ^a   Drent, M ^a,b,e  

^a Dept of Physical Therapy Hospital Gelderse Vallei (ZGV) Ede   (Netherlands)

^b Ild Care Expertise Team Dept of Respiratory Medicine ZGV   (Netherlands)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Exercise limitation; IPF; Physical training; Pulmonary fibrosis; Rehabilitation; Sarcoidosis

Indexed keywords

OXYGEN;

ADULT; ARTICLE; CLINICAL ARTICLE; ENDURANCE TRAINING; EXERCISE; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; MUSCLE STRENGTH; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; OXYGEN CONSUMPTION; PILOT STUDY; PRIORITY JOURNAL; SARCOIDOSIS; SKELETAL MUSCLE; TRAINING; WALKING; ANTHROPOMETRY; BODY MASS; COMPARATIVE STUDY; EXERCISE TOLERANCE; FOLLOW UP; IDIOPATHIC PULMONARY FIBROSIS; KINESIOTHERAPY; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY; RISK ASSESSMENT; SARCOIDOSIS, PULMONARY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAL CAPACITY;

ADULT; ANTHROPOMETRY; BODY MASS INDEX; EXERCISE THERAPY; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; MUSCLE STRENGTH; OXYGEN CONSUMPTION; PILOT PROJECTS; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SARCOIDOSIS, PULMONARY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84937558277     PISSN: 11240490     EISSN: 2532179X     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005; 60 (1): 32-8.
2. Holland A, Hill C. Physical training for interstitial lung disease. Cochrane Database Syst Rev 2008; (4): CD006322.
3. Swigris JJ, Brown KK, Make BJ, Wamboldt FS. Pulmonary rehabilitation in idiopathic pulmonary fibrosis: a call for continued investigation. Respir Med 2008; 102 (12): 1675-80.
4. Braam AW, de Haan SN, Vorselaars AD, et al. Influence of repeated maximal exercise testing on biomarkers and fatigue in sarcoidosis. Brain Behav Immun 2013; 33: 57-64.
5. Baughman RP, Lower EE, Gibson K. Pulmonary manifestations of sarcoidosis. Presse medicale 2012; 41 (6 Pt 2): e289-302.
6. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Muller-Quernheim J. Sarcoidosis. Lancet 2014; 383: 1155-67.
7. Nardi A, Brillet PY, Letoumelin P, et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J 2011; 38 (6): 1368-73.
8. Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc 2013; 10 (4): 362-70.
9. Valeyre D, Nunes H, Bernaudin JF. Advanced pulmonary sarcoidosis. Curr Opin Pulm Med 2014.
10. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188 (6): 733-48.
11. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370 (22): 2071-82.
12. King TE, Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370 (22): 2083-92.
13. Du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183 (9): 1231-7.
14. Marcellis RG, Lenssen AF, Elfferich MD, et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 2011; 38 (3): 628-34.
15. Jackson RM, Gomez-Marin OW, Ramos CF, et al. Exercise limitation in IPF patients: a randomized trial of pulmonary rehabilitation. Lung 2014; 192 (3): 367-76.
16. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008; 63 (6): 549-54.
17. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160 (2): 736-55.
18. Cremers JP, Drent M, Elfferich MD, et al. Body composition profiling in a Dutch sarcoidosis population. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30: 289-99.
19. Lukaski HC, Bolonchuk WW, Hall CB, Siders WA. Validation of tetrapolar bioelectrical impedance method to assess human body composition. J Appl Physiol (1985) 1986; 60 (4): 1327-32.
20. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr 2008; 27 (6): 793-9.
21. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 5-40.
22. Black LF, Hyatt RE. Maximal respiratory pressures: normal values and relationship to age and sex. Am Rev Respir Dis 1969; 99 (5): 696-702.
23. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med 2002; 166 (4): 518-624.
24. Werle S, Goldhahn J, Drerup S, Simmen BR, Sprott H, Herren DB. Age- and gender-specific normative data of grip and pinch strength in a healthy adult Swiss population. J Hand Surg Eur Vol 2009; 34 (1): 76-84.
25. Mathiowetz V, Wiemer DM, Federman SM. Grip and pinch strength: norms for 6- to 19-year-olds. Am J Occup Ther 1986; 40 (10): 705-11.
26. Bohannon RW. Make tests and break tests of elbow flexor muscle strength. Physical therapy 1988; 68 (2): 193-4.
27. Meyer K, Samek L, Schwaibold M, et al. Physical responses to different modes of interval exercise in patients with chronic heart failure - application to exercise training. Eur Heart J 1996; 17 (7): 1040-7.
28. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166 (1): 111-7.
29. Gibbons WJ, Fruchter N, Sloan S, Levy RD. Reference values for a multiple repetition 6-minute walk test in healthy adults older than 20 years. J Cardiopulm Rehabil 2001; 21 (2): 87-93.
30. Michielsen HJ, Drent M, Peros-Golubicic T, De Vries J. Fatigue is associated with quality of life in sarcoidosis patients. Chest 2006; 130 (4): 989-94.
31. De Kleijn WP, De Vries J, Wijnen PA, Drent M. Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. Respir Med 2011; 105 (9): 1388-95.
32. Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J 2012; 40 (1): 255-63.
33. Skevington SM, Pilaar M, Routh D, MaCleod RD. On the language of breathlessness. Psychology & health 1997; 12: 677-89.
34. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006; 173 (12): 1390-413.
35. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14 (5): 377-81.
36. Marcellis RG, Lenssen AF, de Vries GJ, et al. Is There an Added Value of Cardiopulmonary Exercise Testing in Sarcoidosis Patients? Lung 2013; 191 (1): 43-52.
37. Marcellis RG, Lenssen AF, de Vries J, Drent M. Reduced muscle strength, exercise intolerance and disabling symptoms in sarcoidosis. Curr Opin Pulm Med 2013; 19 (5): 524-30.
38. Nishiyama O, Taniguchi H, Kondoh Y, et al. Quadriceps weakness is related to exercise capacity in idiopathic pulmonary fibrosis. Chest 2005; 127 (6): 2028-33.
39. Chura RL, Marciniuk DD, Clemens R, Butcher SJ. Test-Retest Reliability and Physiological Responses Associated with the Steep Ramp Anaerobic Test in Patients with COPD. Pulm Med 2012; 2012: 653831.
40. Vogiatzis I, Simoes DC, Stratakos G, et al. Effect of pulmonary rehabilitation on muscle remodelling in cachectic patients with COPD. Eur Respir J 2010; 36 (2): 301-10.
41. De Vries J, Drent M. Quality of life and health status in sarcoidosis: a review. Semin Respir Crit Care Med 2007; 28 (1): 121-7.
42. Elfferich MD, De Vries J, Drent M. Type D or 'distressed' personality in sarcoidosis and idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28 (1): 65-71.
43. De Vries J, Kessels BL, Drent M. Quality of life of idiopathic pulmonary fibrosis patients. Eur Respir J 2001; 17 (5): 954-61.
44. Marcellis RG, Lenssen AF, Drent M, De Vries J. Association between physical functions and quality of life in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 117-28.
45. De Vries J, Drent M. Relationship between perceived stress and sarcoidosis in a Dutch patient population. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21 (1): 57-63.
46. Swigris JJ, Wamboldt FS, Behr J, et al. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax 2010; 65 (2): 173-7.
47. Verma G, Marras T, Chowdhury N, Singer L. Health-related quality of life and 6 min walk distance in patients with idiopathic pulmonary fibrosis. Can Respir J 2011; 18 (5): 283-7.
48. Cremers JP, Drent M, Bast A, et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med 2013; 19 (5): 545-61.
49. Visca D, Montgomery A, de Lauretis A, et al. Ambulatory oxygen in interstitial lung disease. Eur Respir J 2011; 38 (4): 987-90.
50. Frank RC, Hicks S, Duck AM, Spencer L, Leonard CT, Barnett E. Ambulatory oxygen in idiopathic pulmonary fibrosis: of what benefit? Eur Respir J 2012; 40 (1): 269-70.